Jamie-Lynn
Sigler and Cue Health Announce Product Donation to Multiple
Sclerosis Association of America
SAN
DIEGO, Oct. 6, 2022 /PRNewswire/ -- Cue Health
Inc. (Nasdaq: HLTH), a healthcare technology company, has partnered
with actress Jamie-Lynn Sigler, the
actress best known for her roles on The Sopranos and ABC's
Big Sky, to build awareness for its new Cue Care™
test-to-treatment service. With Cue Care, people who test positive
for COVID-19 on any test, including antigen, can consult virtually
and on-demand with a healthcare professional and easily access
same-day prescription treatment delivered to their home all through
the Cue Health App1.
"Living with multiple sclerosis puts me at higher risk for
severe complications from COVID-19, something I faced head-on when
I tested positive a couple months ago," commented Jamie-Lynn Sigler. "I was so uncertain at that
moment about where to turn and what to do next to keep me and my
family healthy. Cue can now solve that pain point for many people
so they can easily get the medication and peace of mind they need
when they need it the most."
"Jamie's experience shows exactly why Cue is committed to making
treatment fast and accessible through Cue Care," added Clint Sever, co-founder and Chief Product
Officer of Cue Health. "Today, Cue Care advances in the way people
can test and get treatment for COVID-19, and over time it will
enable people who test positive for a variety of infectious
diseases to get treatment without leaving home."
Cue and Sigler are partnering to make a product donation of Cue
Readers and Cue COVID-19 tests to the Multiple Sclerosis
Association of America (MSAA), a leading resource for people like
Sigler who are living with MS in the U.S. With this donation, the
organization will be able to provide lab-quality COVID-19 testing
to members of the community in their own homes who otherwise could
be putting their health at risk by venturing to doctors' offices
and pharmacies.
"The Multiple Sclerosis Association of America is grateful for
the support of Cue Health and Jamie-Lynn
Sigler, which allows us to provide Cue's COVID-19 tests and
Readers to people who are simultaneously managing their MS and the
potential impact of COVID-19," added Gina
Ross Murdoch, MSAA's President and CEO. "MSAA prides itself
on improving the lives of those with MS, and partners like Cue and
Jamie-Lynn help ensure that our clients can maintain their health
and quality of life."
Cue's molecular COVID-19 test is the most accurate
self-test2 available in the United States and provides results
directly to a connected mobile device in 20 minutes. Cue is used in
homes, hospitals and doctor's offices, and by world-class
organizations across the country, including Google, Johns Hopkins
Medicine, Mayo Clinic, the National Basketball Association, and
Major League Baseball, among many others.
Cue Care, a service that is available in the Cue Health App, is
expected to apply to a wide range of tests in the near future.
These include, if approved, Cue flu and flu-COVID-19 molecular
tests, along with tests for other respiratory infections like strep
throat and respiratory syncytial virus (RSV), as well as sexually
transmitted infections including chlamydia and gonorrhea. For more
information about Cue Care and Cue's forthcoming products and
services, please visit shop.cuehealth.com.
Jamie-Lynn Sigler headshot can be
downloaded from HERE.
About Cue Health
Cue Health (Nasdaq: HLTH) is a
healthcare technology company that makes it easier for individuals
to access health information and places diagnostic information at
the center of care. Cue Health enables people to manage their
health through real-time, actionable, and connected health
information, offering individuals and their healthcare providers
easy access to lab-quality diagnostics anywhere, anytime, in a
device that fits in the palm of the hand. Cue Health's
first-of-its-kind COVID-19 test was the first FDA-authorized
molecular diagnostic test for at-home and over-the-counter use
without a prescription and physician supervision. Outside
the United States, Cue Health has
received the CE mark in the European Union, Interim Order
authorization from Health Canada, regulatory approval from
India's Central Drugs Standard
Control Organization, and PSAR authorization from Singapore's Health Sciences Authority. Cue was
founded in 2010 and is headquartered in San Diego. For more information, please visit
www.cuehealth.com.
Forward-Looking Statements
Statements in this press
release about future expectations, plans and prospects, as well as
any other statements regarding matters that are not historical
facts, may constitute "forward-looking statements". The words,
without limitation, "anticipate," "believe," "continue," "could,"
"estimate," "expect," "intend," "may," "plan," "potential,"
"predict," "project," "should," "target," "will," "would" and
similar expressions are intended to identify forward-looking
statements, although not all forward-looking statements contain
these or similar identifying words. Actual results may differ
materially from those indicated by such forward-looking statements
as a result of various important factors, including those related
to the expected future diagnostic test menu and the factors
discussed in the "Risk Factors" section of Cue's Annual Report on
Form 10-K for the year ended December 31,
2021 and Quarterly Report on Form 10-Q for the quarter ended
June 30, 2022 filed with the SEC on
August 10, 2022. Any forward-looking
statements contained in this press release are based on the current
expectations of Cue's management team and speak only as of the date
hereof, and Cue specifically disclaims any obligation to update any
forward-looking statement, whether as a result of new information,
future events or otherwise.
Cue's COVID-19 tests have not been FDA cleared or approved;
but have been authorized by FDA and under an Emergency Use
Authorization (EUA). These products have been authorized only for
the detection of nucleic acid from SARS-CoV-2, not for any other
viruses or pathogens. The emergency use of these products is only
authorized for the duration of the declaration that circumstances
exist justifying the authorization of emergency use of in vitro
diagnostics for detection and/or diagnosis of COVID-19 under
Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21
U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or
authorization is revoked sooner.
1 Medications prescribed by
independent healthcare professionals through Cue Care are subject
to availability and patient eligibility. Cue Health Inc. is not
affiliated with any pharmaceutical manufacturer.
2 Most accurate claim based on
comparison of clinical study results submitted to the U.S. Food and
Drug Administration (FDA) for Emergency Use Authorization for Cue
and other molecular home tests.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/cue-health-partners-with-actress-jamie-lynn-sigler-to-raise-awareness-of-at-home-same-day-test-to-treatment-platform-for-covid-19-and-beyond-301642151.html
SOURCE Cue Health Inc.